Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
15 juil. 2024 06h00 HE
|
Lexeo Therapeutics
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months...
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
11 juil. 2024 08h00 HE
|
Lexeo Therapeutics
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
08 juil. 2024 07h00 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
09 mai 2024 07h00 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
07 mai 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22 avr. 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
16 avr. 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
13 mars 2024 16h22 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
11 mars 2024 07h42 HE
|
Lexeo Therapeutics
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
11 mars 2024 07h30 HE
|
Lexeo Therapeutics
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...